[ad_1]
Vancouver, British Columbia, June 12, 2021 (Global News Agency) – Core One Lab Company (Comprehensive Education:Cool), (Over-the-counter transactions:CLABF), (Frankfurt: LD62, WKN: A2P8K3) (“the company“) is pleased to announce that its wholly-owned subsidiary Vocan Biotechnologies Inc. (“Make a call“), a company operating in one of the few controlled drug and substance distributor laboratories of Health Canada, is pleased to announce that it is in the final stages of completing a provisional patent application to protect its proprietary biological Synthetic psilocybin production system. The application is expected to be submitted in the next few days, and a provisional application will be filed with the U.S. Patent and Trademark Office at that time.
In the past four months, Vocan has made considerable progress in further developing its biosynthetic psilocybin production method, and has begun to collect data to verify the provisional patent we drafted. Therefore, we expect that our provisional patent application will be submitted soon.
The process of extracting the naturally occurring psilocybin from the host plant is inefficient and very expensive, as is the synthetic processing technology. Vocan’s provisional patent application on psilocybin biosynthesis processing solves many of the inefficiencies and cost limitations of current psilocybin production methods. The partnership established with the University of British Columbia (UBC) and the collaborative approach adopted by UBC and Vocan for the production of biosynthetic psilocybin will clearly create the possibility of creating products of the same quality and concentration as their natural compounds in stereochemistry. Core One firmly believes that this collaboration will provide the reliability required for empirical, clinical and medical psychedelic research.
As innovative companies entering the medical psychedelic market continue to grow, and more and more researchers and organizations are eager to further develop the therapeutic and medical benefits of psilocybin, the demand for a stable and consistent supply chain will also increase. Core One believes that its biosynthetic psilocybin production has broad appeal to the global development of psychedelic drugs and clinical industries, and has significant cost reductions and meaningful efficacy enhancements.
“Core One Labs is about to file a patent for its revolutionary biosynthetic psilocybin production system because we only have a few days. This can make the company a leader in providing API-grade psilocybin for the drug, and ultimately can be a shareholder Bring value to stakeholders. We have assembled a world-class team to promote and sell our biosynthetic psilocybin to other major companies dedicated to the treatment of psychedelic solutions. The current price of psilocybin is more than $7,000 per gram, and we think the profit in this area is very high,” Said the company’s CEO Joel Shacker.
About Core One Labs Inc.
Core One is a biotechnology research and technical life science company focused on bringing psychedelic drugs to the market through novel delivery systems and psychedelic-assisted psychotherapy. Core One has developed a patent-pending membrane oral strip (“technology”) that dissolves immediately when placed in the mouth and transports a precise amount of organic molecules into the blood, maintaining excellent bioavailability. The company intends to further develop this technology and apply it to psychedelic compounds such as psilocybin. Core One also has an interest in the medical clinic, which maintains a comprehensive database of more than 275,000 patients. Through the integration of these clinics, their intellectual property rights, and research and development related to psychedelic therapy and new drug therapies, the company plans to obtain regulatory research approval to promote psychedelic-derived therapies for mental health disorders.
Core One Lab Company
Joel Shaq
Chief Executive Officer
For more information, please contact:
info@core1labs.com
1-866-347-5058
Warning disclaimer:
The Canadian Stock Exchange has not reviewed the adequacy or accuracy of the content of this press release and does not assume any responsibility.
The information in this press release contains forward-looking statements based on assumptions as of the date of this press release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They cannot guarantee future performance. The company cautions that all forward-looking statements are inherently uncertain, and actual performance may be affected by many significant factors, many of which are beyond the company’s control. These factors include the risks and uncertainties associated with the company’s limited operating history and the need to comply with strict regulatory requirements. Therefore, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in forward-looking information. Except for applicable securities legislation requirements, the company does not undertake the obligation to publicly update or modify forward-looking information.
In addition, psilocybin is currently a Schedule III drug Controlled Drugs and Substances Act (Canada) Possession of a substance is a criminal offence Controlled Drugs and Substances Act (Canada) Without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One is not directly or indirectly involved in the illegal sale, production or distribution of psychedelic drugs in the jurisdictions in which it operates. Although Core One believes that psychedelic drugs can be used to treat certain diseases, it does not advocate the legalization of psychedelic drugs for recreational use. Core One does not involve psychedelic substances, with the exception of laboratory and clinical trial environments conducted within the approved regulatory framework.
[ad_2]
Source link
